/
IMUX
$15.41+$0.11 (+0.72%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$208.4M
14M shares
52-week range
$5.06 – $15.84
96% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
1.08%
Moderate
Price (6 mo)
Loading chart…
Change$-113.89
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $15.0K | $50.0K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$15.0K | −$50.0K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $24.8M | $22.5M | $38.6M | $61.1M | $71.3M | $83.2M | $80.0M | $82.0M |
| Operating income | −$42.0M | −$37.0M | −$49.0M | −$91.7M | −$119.5M | −$99.2M | −$98.1M | −$103.2M |
| EBITDA | −$15.1M | −$37.0M | −$48.9M | −$92.9M | −$86.4M | −$93.5M | −$100.4M | −$97.0M |
| Net income | −$41.5M | −$34.8M | −$44.0M | −$92.9M | −$120.4M | −$93.6M | −$100.5M | −$97.2M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -391.60 | -45.10 | -28.10 | -39.20 | -37.80 | -21.10 | -10.00 | -6.24 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $13M | $-4.38 | $-6.73–$-2.55 | 8 |
| 2027 | $13M | $-3.55 | $-7.81–$-1.42 | 7 |
| 2028 | $60M | $-3.29 | $-5.64–$-1.49 | 5 |
| 2029 | $232M | $-0.63 | $-0.63–$-0.63 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.60
Price
$15.41
Implied downside
-96%
Peer comparison
Immunic, Inc. Common Stock
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
www.imux.com- Employees
- 95
- IPO / List date
- Apr 17, 2014
- HQ
- NEW YORK, X1
Held by traders on TradeandTell
No one on the platform currently holds IMUX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in IMUX as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-04-27 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded IMUX yet.
